Related references
Note: Only part of the references are listed.Pretransplant identification of acute rejection risk following kidney transplantation
Yvon Lebranchu et al.
TRANSPLANT INTERNATIONAL (2014)
Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients
Robert N. Schuck et al.
ATHEROSCLEROSIS (2013)
ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients
Montserrat Garcia et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
CYP2C8*3 Polymorphism and Donor Age are Associated With Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors
Guillermo Gervasini et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor
Patricia L. Podolin et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2013)
Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects
Dawn Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Soluble Epoxide Hydrolase Activity Determines the Severity of Ischemia-Reperfusion Injury in Kidney
Jung Pyo Lee et al.
PLOS ONE (2012)
Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation
Guillermo Gervasini et al.
TRANSPLANT INTERNATIONAL (2012)
In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy
Jung Pyo Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies
Tsun-Po Yang et al.
BIOINFORMATICS (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2010)
Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice
Craig R. Lee et al.
FASEB JOURNAL (2010)
8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier
Mukut Sharma et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2009)
Living or Deceased Donor Kidney Transplantation: A Comparison of Results and Survival Rates Among Iranian Patients
G. H. Naderi et al.
TRANSPLANTATION PROCEEDINGS (2009)
Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation
S. H. Lee et al.
TRANSPLANTATION PROCEEDINGS (2008)
SNPStats:: a web tool for the analysis of association studies
Xavier Sole et al.
BIOINFORMATICS (2006)
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease:: The Atherosclerosis Risk in Communities (ARIC) study
CR Lee et al.
HUMAN MOLECULAR GENETICS (2006)
Cytochrome P450 and arachidonic acid metabolites:: Role in myocardial ischemia/reperfusion injury revisited
GJ Gross et al.
CARDIOVASCULAR RESEARCH (2005)
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke
M Fornage et al.
HUMAN MOLECULAR GENETICS (2005)
Chronic renal allograft rejection: Pathophysiologic considerations
SA Joosten et al.
KIDNEY INTERNATIONAL (2005)
MDRD equations for estimation of GFR in renal transplant recipients
U Pöge et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases
JD Imig
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure
PK Srivastava et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2004)
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
E Thervet et al.
TRANSPLANTATION (2003)
Polymorphisms in human soluble epoxide hydrolase
BD Przybyla-Zawislak et al.
MOLECULAR PHARMACOLOGY (2003)
Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement
IAM Macphee et al.
TRANSPLANTATION (2002)
Neuroprotection and P4502C11 upregulation after experimental transient ischemic attack
NJ Alkayed et al.
STROKE (2002)
Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase
B Fisslthaler et al.
HYPERTENSION (2001)
Endothelial dysfunction in renal transplant recipients maintained on cyclosporine
STW Morris et al.
KIDNEY INTERNATIONAL (2000)
Share Paper
